Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. by Gray, Emma et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
School of Pharmacy Articles School of Pharmacy
19-4-2017
Effectiveness of triple therapy with direct-acting
antivirals for hepatitis C genotype 1 infection:
application of propensity score matching in a
national HCV treatment registry.
Emma Gray
Trinity College Dublin
David J. Pasta
St. James' Hospital, Dublin
Suzanne Norris
Trinity College Dublin
Aisling O'Leary
Royal College of Surgeons in Ireland, aisoleary@rcsi.ie
Irish Hepatitis C Outcomes and Research Network (ICORN)
This Article is brought to you for free and open access by the School of
Pharmacy at e-publications@RCSI. It has been accepted for inclusion in
School of Pharmacy Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Gray E, Pasta DJ, Norris S, O'Leary A, Irish Hepatitis C Outcomes and Research Network (ICORN). Effectiveness of triple therapy
with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV
treatment registry. BMC Health Services Research. 2017 Apr;17(1):288.
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/spharmart/34
RESEARCH ARTICLE Open Access
Effectiveness of triple therapy with direct-
acting antivirals for hepatitis C genotype 1
infection: application of propensity score
matching in a national HCV treatment
registry
Emma Gray1*, David J. Pasta2, Suzanne Norris1,3, Aisling O’Leary4,5
and on behalf of the Irish Hepatitis C Outcomes and Research Network (ICORN)
Abstract
Background: Observational studies are used to measure the effectiveness of an intervention in non-experimental,
real world scenarios at the population level and are recognised as an important component of the evidence
pyramid. Such data can be accrued through prospective cohort studies and a patient registry is a proven method
for this type of study. The national hepatitis C (HCV) registry was established in Ireland in 2012 with the aim of
monitoring the clinical and economic outcomes from new, high cost regimens for the treatment of HCV infection.
A sustained virological response (SVR) 24 weeks following completion of therapy with interferon-containing
regimens is considered a cure. Non-randomisation in these studies can result in confounding or selection bias.
Propensity score (PS) matching is one of a number of statistical tools that can be used to mitigate the effects of
confounding in observational studies.
Methods: We analysed the data of 309 patients who underwent triple therapy treatment with telaprevir (TPV) in
combination with pegylated-interferon and ribavirin (PR) or boceprevir (BOC)/PR between June 2012 and December
2014. The decision to initiate treatment and the selection of the treatment regimen was at the discretion of the
physician. To adjust for confounding, three approaches to propensity score matching were assessed Adjusted
sustained-virological response rates (SVR), odds ratios, p-values and 95% confidence intervals were calculated from
the three PS matched dataset.
Results: Prior to matching, the unadjusted sustained virological response rates 24 weeks after treatment complete
(SVR24) were 74% (n = 158/215) and 61% (n = 57/94) for telaprevir/PR and boceprevir/PR, respectively. After matching,
adjusted SVR24 rates were between 73–74% and 60–61% for telaprevir/PR and boceprevir/PR, respectively.
Conclusion: Efficacy rates were comparable with those reported in pivotal clinical trials and real world studies. After
adjusting for confounding, we conclude that there was no difference in treatment effect after PS matching. The small
sample size limits the conclusions that can be made about the effect of PS matching. Propensity score adjustment
remains a tool that can be applied to future analysis, however, we suggest, where possible, using a larger sample size
in order to reduce the uncertainty around the outcomes.
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Boceprevir, Sustained virological response
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Background
There is on-going debate about the merits of using ob-
servational evidence either to estimate relative treatment
effect in the absence of randomised evidence or as an
adjunct to it [1–3]. While considered the ‘gold’ standard
in the hierarchy of research designs for evaluating the ef-
ficacy and safety of treatment interventions, the value of
relying on randomised controlled trials (RCTs) for
estimating treatment effectiveness in the clinical setting
is limited [4–6]. This arises from the strict inclusion
and exclusion criteria in these trials, with results
which may have limited applicability to patients in
real-world clinical settings [7, 8].
Observational research is becoming increasingly rec-
ognized as an important component of the evidence
pyramid, as it can provide valuable information regard-
ing the effectiveness and appropriate use of agents in the
real-world, outside of clinical trials [2, 9, 10]. A compre-
hensive evidence base, including both RCTs and high-
quality, well-designed observational studies, is important
and can enhance reimbursement decision providing
decision-makers with a greater evidence-base from which
to make their assessments [4, 6, 11]. The potential for
registries in collecting real world data is substantial [12].
However, the major limitation to this study type is the lack
of randomisation to allocate, by chance, the risk factors
for an outcome of interest [13]. The process of randomisa-
tion ensures that subjects are allocated to treatment or
comparator groups by chance [14]. Absence of random al-
location in observational studies leads to a lack of internal
validity and can result in confounding [4, 15–21].
Confounding is a form of bias that occurs when one
or more variables or risk factors influences the outcomes
of interest and therefore, impacts the true measure of as-
sociation [22]. The non-randomised nature of observa-
tional research studies increases their susceptibility to
confounding bias. While in RCTs, confounding variables
are balanced during the study design phase, the adjust-
ment of confounders in observational studies is com-
pleted during the analysis phase [23]. Propensity score
(PS) matching is one of a number of approaches that
have been developed to reduce confounding. It involves
the generation of a score that summarises the confound-
ing by multiple variables. PS matching involves the for-
mation of matched pairs of treated and untreated
subject. The pairs are formed between subjects with simi-
lar PS values. There are a number of different approaches
to PS matching but nearest neighbour matching without
replacement within a specified caliper limit of the PS is
the most common. This approach will be applied to the
PS matching in this thesis [24–27]. The use of a caliper
limit ensures that the difference in the PS score between
the matched pairs lies within this specified distance. Naïve
matching is also possible, where no limit is placed on the
caliper width. All treated subjects are matched to un-
treated subjects until every subject has been matched.
This method makes the assumption that the distribution
of baseline covariates is similar within a matched pair.
Infection with hepatitis C virus (HCV) is a major pub-
lic health problem and a leading cause of chronic liver
disease [28]. It is estimated to affect >185 million people,
with a prevalence of approximately 3% in the worldwide
population [29]. In Ireland, HCV is estimated to affect
between 20,000 and 50,000 people [30]. Over the last
twenty years, treatment for HCV has evolved rapidly.
Since 2011, with the development of the novel, first gener-
ation directly acting antiviral (DAA) agents telaprevir
(TPV) and boceprevir (BOC), for use in combination with
pegylated-interferon and ribavirin (PR), changed the opti-
mal treatment regimen for genotype (GT) 1 HCV infec-
tion [31]. However, these treatment regimens are complex
and associated with significant side effects, necessitating
intensive on-treatment monitoring. Therefore, the cap-
acity to treat patients in the seven hepatology and infec-
tious disease treatment units in Ireland has been limited.
Given the high drug acquisitions cost of these agents,
epidemiological data indicates the budget impact of
treating the HCV-infected cohort in Ireland to be signifi-
cant and raises the question of affordability [32]. The ap-
proval of these two DAA regimens in Ireland In 2012
was recognized as an opportune time to maximize the
therapeutic management of HCV infection in Ireland.
Thus, a national HCV treatment registry was established
to ensure optimal clinical and economic outcomes from
the use of new agents to the market.
The aim of this study is to determine the clinical out-
comes from the national HCV treatment registry for pa-
tients treated with TPV/PR or BOC/PR and to assess the
application of PS matching in a national registry.
Methods
The Irish national HCV treatment registry utilises a pro-
spective, longitudinal, observational methodology. Since
2012, patients prescribed HCV DAA treatment have
been enrolled for participation in the registry. For this
study, we analysed the data of 309 patients between June
2012 and December 2014. Patients were eligible if they
were HCV GT1 infected and 18 years or older. Cirrhotic
and non-cirrhotic patients, those with or without a his-
tory of previous HCV treatment exposure and HIV co-
infected patients were eligible for inclusion.
The decision to initiate treatment and the selection of
the treatment regimen was at the discretion of the phys-
ician. Patients were treated with either:
a) Telaprevir in combination with pegylated interferon
and ribavirin (TPV/PR)
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b) Boceprevir in combination with pegylated interferon
and ribavirin (BOC/PR)
Demographic and clinical data were collected at base-
line, throughout treatment and in the post-treatment fol-
low-up period. Treatment effectiveness was measured as
sustained virological response 24-weeks post treatment
completion (SVR24). SVR24 was defined as HCV-RNA
level below the level of quantification or undetected re-
corded at least 24 weeks after cessation of treatment.
Where a SVR was not achieved, the frequency of viro-
logical failure and relapse were recorded. Additionally, pa-
tients who were lost-to-follow up or had discontinued
treatment prematurely as a result of adverse events, non-
compliance or other factors were captured.
Statistical analysis
Descriptive statistics were used to present the baseline
characteristics and unadjusted outcomes for the study
population. Categorical variables were reported as frequen-
cies and percentages. Baseline continuous data were
expressed as medians (with the interquartile range (IQR)).
Univariate analyses were performed using Chi-square,
Fisher’s Exact or Student’s t-test as appropriate. The SVR24
was measured on an ‘intent-to-treat’ basis with all patients
starting treatment contributing to the denominator.
The numbers of patients included in the study were lim-
ited by the capacity to treat in the designated treatment
clinics in Ireland at the time. We included all patients
who received treatment with TPV/PR or BOC/PR in the
defined period of the study which was 309. This number
does not have sufficient power to demonstrate statistical
significance. Therefore, conclusions about the statistical
significance and treatment effect are therefore, limited.
The PS, the probability of being treated with TPV/PR,
as opposed to BOC/PR, given other known baseline
demographics and HCV characteristics, was computed
using logistic regression. Following a review of the litera-
ture and consultation with clinicians, nine covariates were
entered into the model: previous treatment experience,
presence of cirrhosis, age, BMI, GT1, GT1b, IL28B CT,
IL28B TT and baseline HCV > 800,000 IU/ml [33–37]. For
both genotype and IL28B allele, both of which had more
than two distinct categories (i.e., GT1 (no subtype), GT1a,
GT1b), dummy variables were created to represent these
subgroups in the regression analysis (Additional file 1:
Tables S1 and S2). The resultant PS (range = 0.0–1.0) was
a single score per patient, with a high score repre-
senting a high probability that the patient would be
treated with TPV/PR, based on the given information.
Prior to applying PS matching, a comparison of con-
founders between the TPV/PR and BOC/PR groups
was completed. The standardised difference was used
to compare the mean of continuous and binary
variables between treatment groups and is not influ-
enced by the sample size.
Three approaches to nearest neighbor matching with-
out replacement were employed to match patients who
received TPV/PR with patients who received BOC/PR. A
treated subject (TPV/PR) was first selected at random.
The untreated subject (BOC/PR) whose PS was closest
to that of this randomly selected treated subject was
chosen for matching. This process was then repeated
until untreated subject have been matched to all treated
subjects. In our first approach, naïve matching was used
(no limit was placed on the caliper width) whereby all
ninety-four BOC/PR subjects were matched to a TPV/
PR subject. A second matching approach was completed
where patients were matched on the logit of the PS
using a caliper width equal to 0.1 of the logit of the PS.
Finally, in the third scenario, the caliper width was ex-
tended to 0.2 of the logit of the PS. In all three ap-
proaches, each TPV/PR treated subject was matched to
the BOC/PR subject with the closest PS. Adjusted SVR
rates, odds ratios (OR), p-values and 95% confidence in-
tervals (CI) were calculated.
Demographic and outcome analyses and multiple
imputation were conducted using SPSS Version 21 (IBM
Corp, Armonk, NY, USA) [38]. PS matching was
conducted with STATA Version 14 (STATACorp, College
Station, Texas, USA) [39].
Results
A total of 309 patients with HCV infection initiated
treatment with TPV/PR (n = 215) or BOC/PR (n = 94).
All have reached SVR24 (n = 222/309) or discontinued
treatment prematurely (n = 87/309). The majority of pa-
tients were male (73.1%) with a median age of 46 years
(IQR 38–54 years). Patients who previously failed to re-
spond to treatment with PR accounted for 29.1% of the
cohort while cirrhosis was present in 27.1%. HIV co-
infection accounts for 7.3%. IL28B CT was the dominant
(53.5%) allele. The proportion of patients with GT1a, 1b
and 1 (no subtype) was 55.7, 27.8 and 16.5% respectively.
Baseline HCV-RNA was greater than 800,000 IU/ml in
53.5% of the cohort (Table 1).
Effectiveness
Outcomes for all 309 patients are presented in Table 2.
Overall, 72% (n = 222/309) of the cohort completed ther-
apy, with the remaining 28% (n = 87/309) discontinuing
early due to adverse events (AEs), virological failure, poor
tolerability, non-compliance or for an undetermined
reason. The overall rate of SVR24 (unadjusted) was 70%
(n = 215/309). This included fifteen patients who discon-
tinued prematurely as a result of an AE or non-
compliance but achieved an SVR24. Fourteen patients
(5%) completed a full course of treatment but relapsed
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within 24-weeks of completing therapy. There were eight
patients (2%) considered lost to follow-up. These patients
completed a full course of therapy but failed to return to
the clinic for any SVR assessment (Fig. 1).
The unadjusted SVR24 rates were 74% (n = 158/215)
and 61% (n = 57/94) for TPV/PR and BOC/PR, respect-
ively. Discontinuation and relapse rates were comparable
between the two treatments (Fig. 2). Prior to adjusting for
confounding, the crude odds of SVR in patients treated
with TPV/PR were 80% greater than those treated with
BOC/PR (OR = 1.8, 95% CI 1.08–3, p = 0.025).
The unadjusted SVR24 rates varied according to the
presence or absence of baseline cirrhosis, prior treat-
ment experience and GT1 subtype (Table 2). In the ab-
sence of cirrhosis, the SVR24 was 79% (n = 113/143) for
patients treated with TPV/PR and 65% (n = 45/69) for
Table 1 Baseline demographics of the cohort
Total Cohort TPV/PR BOC/PR
n = 309 n = 215 n = 94
Age – Years, Median (IQR) 46 (38–54) 45 (38–54) 47 (39–56)
BMI – kg/m2 Median (IQR) 26.5 (23.5–28.8) 26.3 (23.9–28.5) 25.9 (21.4–30.6)
Male, n (%) 212/290 (73.1%) 149/202 (73.8%) 63/88 (71.6%)
History of cirrhosis, n (%) 79/291 (27.1%) 55/198 (27.8%) 24/93 (25.8%)
Treatment Experienced, n (%) 89/306 (29.1%) 66/212 (31.1%) 23/94 (24.5%)
HIV co-infected, n (%) 23/313 (7.3%) 23/198 (11.6%) –
IL28B Allele, n (%)
CC 92/269 (34.2%) 59/179 (33%) 31/86 (36%)
CT 144/269 (53.5%) 96/179 (53.6%) 47/86 (54.5%)
TT 33/269 (12.3%) 24/179 (13.4%) 8/86 (9.3%)
Genotype, n (%)
G1a 172/309 (55.7%) 119/215 (55.3%) 53/94 (56.4%)
G1b 86/309 (27.8%) 55/215 (25.6%) 31/94 (33%)
G1 – unspecified 51/309 (16.5%) 41/215 (19.1%) 10/94 (10.6%)
Acquisition Risk Factor
IVDU 133/309 (43%) 89/215 (41.7%) 44/94 (46.8%)
Anti-D 28/309 (9.1%) 18/215 (8.4%) 10/94 (10.6%)
Blood product 36/309 (11.7%) 31/215 (14.4%) 5/94 (5.3%)
Other 15/309 (4.9%) 11/215 (5.1%) 4/94 (4.4%)
Unknown/not reported 97/309 (31.4%) 66/215 (30.7%) 31/94 (32.9%)
Baseline HCV-RNA >800,000 IU/ml 153/286 (53.5%) 98/196 (50%) 55/90 (61.1%)
Missing data is a common problem with observational data. Percentages are calculated based on the proportion of available data
Table 2 Unadjusted SVR rates among patients stratified by treatment choice and baseline HCV characteristics
Total
N = 309
TPV/PR
N = 215
BOC/PR
N = 94
n/N SVR12 95% CI n/N SVR12 95% CI n/N SVR12 95% CI
Overall 215/309 69.6 64.5–74.7 158/215 73.5 67.6–79.4 57/94 60.6 50.7–70.5
Absence of cirrhosis 158/212 74.5 68.6–80.4 113/143 79 72.3–85.7 45/69 65.2 54–76.4
Presence of cirrhosis 48/79 60.8 47.8–69.2 36/55 65.5 52.9–78.1 12/24 50 30–70
Treatment naïve 153/217 70.5 64.4–76.6 109/146 74.7 67.6–81.8 44/71 56.5 36.2–76.4
Treatment experienced 61/89 68.5 58.8–78.2 48/66 72.7 62–83.4 13/23 62 50.7–73.3
Genotype 1a 115/172 66.9 59.9–73.9 84/119 70.6 62.4–78.8 31/53 58.5 45.2–71.8
Genotype 1b 64/86 74.4 65.2–83.6 46/55 83.6 78.8–93.4 18/31 58.1 40.7–70.5
Genotype 1 (no subtype) 35/49 71.4 58.7–84.1 27/39 69.2 54.7–83.7 8/10 80 55.2–104.8
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Fig. 1 Flow diagram illustrating the outcomes of patients ever started on treatment with TPV/PR and BOC/PR. #Fifteen patients discontinued
treatment prematurely but achieved a SVR24. Therefore, in total n = 215/309 (70%) (n = 200/222 and n = 15/87) achieved a SVR24
Fig. 2 Unadjusted treatment outcomes for the overall cohort and stratified per treatment regimen. # Fifteen patients discontinued treatment
prematurely but achieved an SVR24; eleven patients treated with TPV/PR and four patients treated with BOC/PR. These patients were counted in
both the discontinuation rate and the SVR rate
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patients treated with BOC/PR. Presence of cirrhosis led
to SVR24 rates of 66% (n = 36/55) and 50% (12/24) in
TPV/PR and BOC/PR cohorts, respectively.
The SVR24 for treatment naïve patients treated with
TPV/PR was 75% (n = 109/146) and 57% (n = 44/71) for
patients who received BOC/PR. Previous treatment ex-
perience resulted in SVR24 rates of 73 and 62% in those
treated with TPV/PR and BOC/PR respectively. The
SVR24 rates were higher in GT1a and GT1b patients
treated with TPV/PR compared with those treated with
BOC/PR (71% and 84% vs. 59% and 58% for GT1a and
GT1b TPV/PR and BOC/PR, respectively).
Propensity score matched analysis
Prior to applying PS matching, a comparison of con-
founders between the TPV/PR and BOC/PR groups
was completed. The standardised difference of con-
founding variables prior to matching is presented in
Table 3. Variables with a standardised difference
greater than 0.1 exhibit imbalance between the two
treatment groups.
Naïve matching
After matching, ninety-four matched pairs were formed.
The standardised difference of confounding variables
after naïve matching shows improvements in balance be-
tween the two groups (Table 4).
The adjusted SVR rates were 73% (n = 69/94) and 61%
(n = 57/94) for TPV/PR and BOC/PR, respectively. The
adjusted odds of SVR in patients treated with TPV/PR
were 76% greater than those treated with BOC/PR (OR =
1.76, 95% CI 0.868–3.58, p = 0.116).
Matching with a 0.1 Caliper Limit
After matching, applying a caliper width limit of 0.1,
ninety matched pairs were formed. Four pairs were ex-
cluded after the caliper limit was applied due a difference
in the logit of the PS being greater than 0.1. The con-
founding variables after matching shows greater balance
than prior to matching (Table 4).
The adjusted SVR rates were 73% (n = 66/90) and 60%
(n = 54/90) for TPV/PR and BOC/PR, respectively. The ad-
justed odds of SVR in patients treated with TPV/PR were
87% greater than those treated with BOC/PR (OR = 1.87,
95% CI 0.89–3.95, p = 0.097).
Matching with a 0.2 Caliper Limit
After adjusting the caliper width limit to 0.2, ninety-one
matched pairs were formed. Three pairs were excluded
after the caliper width limit of 0.2 was applied. After
matching, the standardised difference for all covariates is
less than 0.1 (Table).
The adjusted SVR rates were 74% (n = 67/91) and 60%
(n = 57/91) for TPV/PR and BOC/PR, respectively. The
adjusted odds of SVR in patients treated with TPV/PR were
85% greater than those treated with BOC/PR (OR = 1.85,
95% CI 0.883–3.88, p = 0.102).
Figure 3 illustrates the SVR24 rates for TPV/PR and
BOC/PR prior to and after applying the PS matching
methodology. There is no significant change in the treat-
ment effect after PS matching.
Comparison with clinical trial data
Pivotal TPV/PR and BOC/PR clinical trials were under-
taken exclusively in treatment naïve or treatment experi-
enced patients [40–45]. Comparison of the adjusted
outcomes from this study with clinical trial data demon-
strates that the adjusted SVR rates in both the TPV/PR
and BOC/PR groups are comparable to those obtained
in the clinical trials. In the TPV/PR treatment experience
group, the adjusted SVR rates in this study demonstrate
an improvement on the SVR rates obtained in the trials
while the adjusted SVR rates for the BOC/PR treatment
Table 3 Standardised difference of confounding variables
between TPV/PR and BOC/PR patients prior to matching
Mean TPV/PR Mean BOC/PR Standardised
difference
Treatment experinced 0.31 0.24 0.154
Presence of cirrhosis 0.29 0.26 0.058
Age 45.73 47.62 −0.174
BMI 26.7 26.73 −0.006
Baseline HCV > 800,000 0.49 0.6 −0.203
GT1 0.19 0.11 0.225
GT1b 0.26 0.33 −0.153
IL28B CT 0.49 0.53 −0.072
IL28B TT 0.17 0.11 0.119
Table 4 Standardised difference of confounding variables
between TPV/PR and BOC/PR patients after the three
approaches to matching
After naïve
matching
After 0.1
caliper limit
After 0.2
caliper limit
Treatment experinced 0.000 0.04 0.04
Presence of cirrhosis 0.000 0.022 0.022
Age −0.014 0.011 0.016
BMI −0.003 −0.005 −0.002
Baseline HCV > 800,000 0.019 0.019 0.019
GT1 −0.022 0.000 0.000
GT1b 0.019 0.039 0.039
IL28B CT 0.018 −0.018 −0.018
IL28B TT 0.027 0.072 0.028
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experienced are lower in this study when compared with
the clinical trial data (Fig. 4).
Comparison with real world studies
A number of other real world studies assessing the ef-
fectiveness of TPV/PR and BOC/PR were initiated in the
USA and Europe. We directly compared the SVR24 rates
from our cohort with outcomes reported in the US-
based HCV-TARGET study and the German-based PAN
study (Fig. 5) [46, 47]. In the TPV/PR cohorts, a statisti-
cally significant difference was observed in the SVR24
rates between this study and both the HCV-TARGET
and PAN studies (p < 0.05). In the BOC/PR cohorts, a
statistically significant difference was observed between
our study and the HCV-TARGET (p < 0.05) study but
the difference between our study and the PAN study was
not statistically significant (p = 0.141).
Discussion
PS matching was applied to this dataset and is one of a
number of tools that can be used to address the limitation
due to confounding in non-randomised studies. It enables
one to design and analyse an observational study so that it
mimics some of the characteristics of a randomized con-
trolled trial [48]. Random allocation allows conclusions to
be made about the effect of treatment on outcomes by
making direct comparisons between treated and untreated
subjects, or between two treatment groups.
Prior to implementing PS matching there was an im-
balance between confounding variables in the two treat-
ment groups. While there is no international criterion
that defines covariate imbalance, a standardised difference,
between covariates of treated and untreated subjects, less
than 0.1 is commonly accepted. This is taken to indicate a
negligible difference in covariate balance between treatment
Fig. 3 Adjusted SVR rates after propensity score matching for TPV/PR and BOC/PR treated patients
Fig. 4 Comparison of the SVR24 rates between pivotal clinical trials and this study after adjusting for confounding
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groups [48]. Prior to matching, six of the nine covariates
had a standardised difference greater then 0.1.
In order to improve the certainty surrounding our out-
comes after PS matching, three approaches to PS match-
ing were utilized. Naïve matching was the first approach
to PS matching used. After matching, the standardised
difference for each covariate was <0.1, indicating balance
between the two groups. The logit of the propensity
scores of the matched pairs was examined. The dif-
ference in logit of the final four pairs in each of the
imputed datasets was considered poor (>0.2) and un-
acceptable. No significant impact on treatment effect
was observed. The p-value for the odds ratio indicated
that there was no statistically significant difference be-
tween TPV/PR and BOC/PR groups (p-value = 0.116),
contradicting the crude odds ratio calculated before
matching (p-value = 0.025). Given the unacceptability of a
number of matched pairs, the matching was repeated, ap-
plying a caliper width limit of 0.1; the difference in logit of
matches could not differ by more than 0.1. Ninety
matched pairs were created. Standardised differences indi-
cated balance between the TPV/PR and BOC/PR groups.
Again, propensity score matching did not impact the
SVR24 rate and the p-value indicated that there was no
statistically significant difference between the two treat-
ment groups (p-value = 0.097). A final, intermediate
matching approach was implemented and a caliper width
limit of 0.2 was applied. Ninety-one matched pairs were
created and balance was observed between covariates in
the two treatment groups. Analysis of the p-value indi-
cated that there was no statistically significant difference
in the odds of a SVR24 between the two groups and there
was no impact on treatment effect.
After completing the three approaches to PS matching
and adjusting for confounding in our data, balance in
confounding variables between the two groups was ob-
served. However, there was no difference in the SVR24
rates of the TPV/PR and BOC/PR groups prior to, and
after PS matching (Fig. 3) While p-values after matching
contrasted with the p-value before matching, the wide
confidence intervals indicate significant uncertainty sur-
rounding the outcomes.
Data reported in the Irish national HCV treatment
registry confirms that the effectiveness in HCV treat-
ment regimens in the Irish real world setting is generally
comparable to the efficacy rates reported in clinical trials
for similar patient cohorts, taking into account that his-
torically, translation of outcomes from clinical trials is
lower than in the clinical setting. Comparison of the
SVR24 rates in the TPV/PR treatment naïve and
treatment experienced subgroups in this study with
the ADVANCE and ILLUMINATE treatment naïve,
and REALIZE treatment experienced clinical trials in-
dicate that the results in the real-world clinical set-
ting are comparable, or better, than those reported in
these trials [40–42]. The adjusted SVR24 rates in our
TPV/PR treatment experienced group were between 7
and 10% higher than those observed in the REALIZE
trial. The adjusted SVR24 rates in our BOC/PR treat-
ment naïve group are comparable with outcomes
from the SPRINT-1 and SPRINT-2 clinical trials but
the results in the RESPOND trial are approximately
5% greater than the adjusted SVR24 rates in our
BOC/PR treatment experienced group [43–45].
Additionally, the SVR outcomes were also compared
with other international real world studies. The SVR24
rate from the Irish national HCV registry compared
favourably with the outcomes from other international
real world studies [46, 47]. Comparing key baseline demo-
graphics and HCV characteristics between the three stud-
ies demonstrated that our cohort was younger and had a
higher proportion of males. However, our Irish cohort did
include a lower proportion of patients with previous treat-
ment experience while the proportion of patients with cir-
rhosis was lower than in the HCV-TARGET study but
higher than the proportion in the PAN study [46, 47].
Fig. 5 Comparison of the SVR24 rates between the Irish national registry and other international real world studies
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These demographic details suggest that the cohorts in the
HCV-TARGET and PAN studies would be considered
more difficult-to-treat than the Irish cohort and therefore,
is reflected in the lower SVR24 rates reported in these
studies.
Conclusion
This study presents the effectiveness of triple therapy
DAA regimens in a real-world clinical setting. PS match-
ing is a useful tool for assessing real-world effectiveness
while reducing the imbalance in confounding variables
that exist in non-randomised studies. It generates ad-
justed outcome data that can be subsequently compared
with clinical trial efficacy data. In this study, we con-
clude that there was no difference in the SVR24 rates of
the TPV/PR and BOC/PR groups prior to, and after PS
matching. The small sample size limits the conclusions
that can be made about the effect of PS matching. While
statistical significance was reported, the wide confidence
intervals indicate significant uncertainty surrounding the
outcomes. Propensity score adjustment remains a tool
that can be applied to future analysis. However, we sug-
gest, where possible, using a larger sample size in order
to reduce the uncertainty around the outcomes.
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